Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. (Nasdaq: ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering a novel therapeutic approach known as immuno-neurology. The company leverages the body’s innate immune system to develop treatments for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). Alector’s groundbreaking research focuses on counteracting brain pathologies by restoring healthy immune function.
The company’s pipeline includes several promising product candidates like AL001 (latozinemab), AL002, AL003, and AL101. Among these, latozinemab and AL101 are being co-developed in collaboration with global biopharmaceutical giant GSK. Latozinemab, a progranulin-elevating monoclonal antibody, is currently in the pivotal Phase 3 INFRONT-3 trial for FTD-GRN and has received FDA Breakthrough Therapy and Fast Track designations.
AL002, in collaboration with AbbVie, is a TREM2-activating antibody undergoing a Phase 2 INVOKE-2 trial to assess its efficacy in early Alzheimer's disease. The company recently completed enrollment for INVOKE-2, with a data readout expected in the fourth quarter of 2024. AL101, another progranulin-elevating candidate, has initiated the PROGRESS-AD Phase 2 trial to treat early Alzheimer's disease.
Alector’s innovative Alector Brain Carrier (ABC) technology aims to enhance drug delivery across the blood-brain barrier, further strengthening their therapeutic pipeline. The company’s financial health is robust, with $620.0 million in cash, cash equivalents, and investments as of January 2024. This financial buffer is anticipated to fund operations through 2026, ensuring continued progress in their clinical programs.
For ongoing updates and detailed information, visit their official website at www.alector.com.
Alector, Inc. (Nasdaq: ALEC) reported promising outcomes from its Phase 2 INFRONT-2 study of AL001, targeting frontotemporal dementia (FTD) due to progranulin gene mutations. At the Alzheimer’s Association International Conference, data showed that AL001 restored progranulin to normal levels and slowed clinical progression by 47% compared to a matched control group. Safety results indicated a favorable profile with mild adverse effects in a small patient cohort. Alector plans to proceed with a Phase 3 study, further assessing AL001's efficacy and safety in FTD patients.
Alector, Inc. (Nasdaq: ALEC) announced an oral presentation on July 29, 2021, regarding the Phase 2 study of AL001 for frontotemporal dementia with a progranulin mutation, at the 2021 Alzheimer’s Association International Conference. The six- and twelve-month data from the open-label INFRONT-2 study will be discussed by Dr. Robert Paul, CMO. Additionally, two posters will present the AL002 Alzheimer’s disease program, including Phase 1 study results and INVOKE-2 trial design. The conference call will be held at 1:00 p.m. ET to review findings.
Alector and GSK have formed a strategic collaboration to co-develop monoclonal antibodies AL001 and AL101 aimed at treating multiple neurodegenerative diseases. This partnership includes a $700 million upfront payment and up to $1.5 billion in potential milestones. Alector will lead clinical development up to Phase 2, while both companies will share commercialization responsibilities in the U.S., with GSK handling international rights. The collaboration could significantly expand treatment options for conditions like frontotemporal dementia, ALS, Parkinson's, and Alzheimer’s.
Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced that Dr. Shehnaaz Suliman will participate in two upcoming investor conferences. The events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 4:40 p.m. ET, and the BofA Securities 2021 Napa Biopharma Virtual Conference on June 14, 2021, at 5:30 p.m. ET. Live webcasts will be accessible on Alector's website, with replays available for 30 days post-event. Alector is focused on developing therapies for neurodegenerative diseases by targeting immune dysfunction.
Alector, Inc. (Nasdaq: ALEC) announced a virtual key opinion leader event on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) scheduled for June 11, 2021, at 10:30 a.m. ET. The agenda includes discussions on FTD-GRN pathophysiology, clinical endpoints, and disease-relevant biomarkers. Key presentations will be made by esteemed neurology experts, including Henrik Zetterberg and Jonathan Rohrer. The event will be webcast live on Alector's website. AL001, an investigational monoclonal antibody for FTD-GRN, has received Orphan Drug and Fast Track designations from the FDA.
Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced participation by its president and COO, Shehnaaz Suliman, in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:45 a.m. ET. A live webcast will be accessible on the Alector website, with a replay available for 30 days post-event. Alector focuses on innovative therapies for neurodegenerative diseases, emphasizing innate immune system repair and targeting genetic mutations in neurodegenerative conditions.
Alector, Inc. (Nasdaq: ALEC) reported key business updates and financial results for Q1 2021. The company is actively enrolling patients in the AL001 INFRONT-3 Phase 3 trial for frontotemporal dementia and the AL002 INVOKE-2 Phase 2 trial for early Alzheimer's disease. Collaboration revenue dropped to $4.1 million from $7.2 million year-over-year. R&D expenses rose significantly to $45.7 million, contributing to a net loss of $52.2 million, up from $40 million in Q1 2020. Cash, cash equivalents, and marketable securities totaled $362.7 million as of March 31, 2021.
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced that its president, Shehnaaz Suliman, will participate in a fireside chat at Stifel’s 3rd Annual CNS Day on April 1, 2021, at 9:30 a.m. ET. The event will be accessible via a live webcast on the Alector website, with a replay available for 30 days afterward. Alector is pioneering treatments for neurodegenerative diseases by targeting immune dysfunction, particularly in Alzheimer's and frontotemporal dementia patient populations.
Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on immuno-neurology, announced participation in the Barclays Global Healthcare Conference on March 11, 2021, at 2:25 p.m. ET by COO Shehnaaz Suliman, M.D. A live webcast will be available on Alector's Investors page, with a replay accessible for 30 days post-event. Alector is developing innovative therapies targeting neurodegenerative diseases, utilizing innate immune system programs to address immune dysfunction in conditions like Alzheimer's and frontotemporal dementia. Visit www.alector.com for more information.
Alector, Inc. (NASDAQ: ALEC) reported business updates and financial results for Q4 2020, highlighting significant progress in its clinical programs. The company initiated the AL001 INFRONT-3 Phase 3 trial for frontotemporal dementia and AL002 INVOKE-2 Phase 2 trial for early Alzheimer's disease. Revenue for Q4 was $4.9 million, down from $6.0 million YoY, with a total 2020 revenue of $21.1 million, relatively stable. R&D expenses surged to $44.4 million for Q4, contributing to a net loss of $52.2 million. Alector's cash position remains strong at $413.3 million, sufficient to fund operations through mid-2022.
FAQ
What is the current stock price of Alector (ALEC)?
What is the market cap of Alector (ALEC)?
What is Alector, Inc. known for?
What are the main product candidates in Alector's pipeline?
What recent achievements has Alector accomplished?
Who are Alector's key collaborators?
What is the focus of Alector's immuno-neurology approach?
When is the data readout for the INVOKE-2 trial expected?
What is the Alector Brain Carrier (ABC) technology?
What financial condition is Alector currently in?
What is the significance of the FDA Breakthrough Therapy Designation for latozinemab?
Where can more information about Alector be found?
